ImmuCell Corporation Announces Board Changes and Director Appointment
PORTLAND, ME – March 18, 2026 – ImmuCell Corporation (NASDAQ: ICCC), a leading developer in in vitro and in vivo diagnostic substances, has released a Form 8-K Current Report announcing significant changes to its Board of Directors. The company’s latest SEC filing may have implications for shareholders and could impact the value of ICCC shares.
Key Points from the 8-K Filing
- Board Departure: Steven A. Rosgen, a current director, has notified ImmuCell that he will not stand for re-election to the Board of Directors. This departure was previously disclosed in the Company’s 8-K filed on February 9, 2026.
- Director Appointment: ImmuCell has elected Ms. Turner as a new member of the Board of Directors, effective March 12, 2026.
- No Related Party Transactions: The company stated it is not aware of any transaction involving Ms. Turner that would require disclosure under Item 404(a) of Regulation S-K.
- Press Release: A copy of the press release announcing Ms. Turner’s election as director is furnished as Exhibit 99.1.
Details Investors Should Note
- Leadership Transition: The departure of Mr. Rosgen and the appointment of Ms. Turner mark a notable shift in board composition. Leadership changes at the board level are closely watched by investors, as they can signal changes in company strategy or governance. Such events may influence investor confidence and affect share price.
- Regulatory Compliance: The report confirms that there are no transactions requiring disclosure under Item 404(a), which addresses related party transactions and potential conflicts of interest. This transparency may reassure investors about the integrity of the new appointment.
- Emerging Growth Company Status: ImmuCell has indicated it is not an emerging growth company under SEC rules. This means the company is subject to standard financial reporting requirements and does not benefit from extended transition periods for new or revised accounting standards.
- Securities Information: ImmuCell’s common stock, with a par value of \$0.10 per share, trades under the symbol ICCC on the Nasdaq Capital Market.
Potential Price Sensitive Information
- Board Changes: Investors often react to changes in board composition, especially when it involves long-serving directors or the introduction of individuals with potentially new strategic perspectives.
- Director Appointment: While the background and potential impact of Ms. Turner is not detailed in the filing, her election could signal upcoming changes in company direction, priorities, or performance. Shareholders should monitor future communications for updates on Ms. Turner’s role and contributions.
- No Indication of Material Cybersecurity Incidents: The filing does not report any material cybersecurity incidents or other adverse events, which is important for maintaining shareholder confidence in the company’s operational stability.
Contact Information
For further information, investors can contact:
- Olivier te Boekhorst, President and CEO
- Timothy C. Fiori, Chief Financial Officer
- Email: [email protected]
Investor relations are also managed by Joe Diaz, Robert Blum, and Joe Dorame at Lytham Partners, LLC ([email protected]).
Conclusion
The departure of Steven A. Rosgen and the appointment of Ms. Turner to the Board of Directors are important developments for ImmuCell Corporation. Investors should pay attention to further details regarding Ms. Turner’s background and her potential impact on company strategy, as these changes may influence market perceptions and share value.
Disclaimer: This article is based on information disclosed in ImmuCell Corporation’s SEC Form 8-K filing dated March 18, 2026. It is intended for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The author is not responsible for any actions taken based on this article.
View IMMUCELL CORP /DE/ Historical chart here
